Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae (also known as pneumococcus). It causes contagious and potentially severe illness, including pneumonia, meningitis and sepsis, so early diagnosis and treatment is important. Vaccines have been the best protection against developing infection. The purpose of this study is to measure whether an investigational pneumococcal vaccine is safe and can help the body to develop germ-fighting agents called “antibodies” (immunogenicity) compared with 20-valent pneumococcal vaccine (licensed pneumococcal conjugate vaccine) when given to infants, toddlers, children, and adolescents.

The potential benefits to participants would be study-related medical care at no-cost and compensation for study related efforts and travel. On a wider scale, there may be general benefits to society because the investigational treatment may become a future treatment option.

To qualify for the study, your child must be:

• Aged 7 months to 17 years on the day of inclusion.
• Healthy as determined by medical evaluation including medical history and physical examination
• (For Infants and Toddlers Only) Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg or born after a gestation period above 28 (> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 kg, and in both cases medically stable as assessed by the investigator.
• Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.